about
Human osteoclast-poor osteopetrosis with hypogammaglobulinemia due to TNFRSF11A (RANK) mutationsThe putative cannabinoid receptor GPR55 affects osteoclast function in vitro and bone mass in vivoInvolvement of PLEKHM1 in osteoclastic vesicular transport and osteopetrosis in incisors absent rats and humansOsteoclasts control reactivation of dormant myeloma cells by remodelling the endosteal niche.Osteoclasts on bone and dentin in vitro: mechanism of trail formation and comparison of resorption behaviorMolecular mechanisms of action of bisphosphonates.Protein geranylgeranylation is required for osteoclast formation, function, and survival: inhibition by bisphosphonates and GGTI-298.Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy.A role for L-alpha-lysophosphatidylinositol and GPR55 in the modulation of migration, orientation and polarization of human breast cancer cells.The mesenchymal stem cell marker CD248 (endosialin) is a negative regulator of bone formation in mice.Clodronate and liposome-encapsulated clodronate are metabolized to a toxic ATP analog, adenosine 5'-(beta, gamma-dichloromethylene) triphosphate, by mammalian cells in vitro.The molecular mechanism of nitrogen-containing bisphosphonates as antiosteoporosis drugs.The matricellular protein CYR61 inhibits osteoclastogenesis by a mechanism independent of alphavbeta3 and alphavbeta5.Real-time intravital imaging establishes tumor-associated macrophages as the extraskeletal target of bisphosphonate action in cancerImpaired prenylation of Rab GTPases in the gunmetal mouse causes defects in bone cell function.Fluorescent risedronate analogues reveal bisphosphonate uptake by bone marrow monocytes and localization around osteocytes in vivoSynthesis and characterization of novel fluorescent nitrogen-containing bisphosphonate imaging probes for bone active drugs.Mechanisms of osteopontin and CD44 as metastatic principles in prostate cancer cells.From molds and macrophages to mevalonate: a decade of progress in understanding the molecular mode of action of bisphosphonates.Signal peptide mutations in RANK prevent downstream activation of NF-κB.The ADP receptor P2RY12 regulates osteoclast function and pathologic bone remodeling.Molecular mechanisms of action of bisphosphonates: current status.A highly sensitive prenylation assay reveals in vivo effects of bisphosphonate drug on the Rab prenylome of macrophages outside the skeleton.Phosphonocarboxylates inhibit the second geranylgeranyl addition by Rab geranylgeranyl transferase.Bisphosphonates: molecular mechanisms of action and effects on bone cells, monocytes and macrophages.Biochemical and molecular mechanisms of action of bisphosphonates.Functional interaction between sequestosome-1/p62 and autophagy-linked FYVE-containing protein WDFY3 in human osteoclasts.Synthesis, chiral high performance liquid chromatographic resolution and enantiospecific activity of a potent new geranylgeranyl transferase inhibitor, 2-hydroxy-3-imidazo[1,2-a]pyridin-3-yl-2-phosphonopropionic acid.The bisphosphonate zoledronic acid has antimyeloma activity in vivo by inhibition of protein prenylation.The bisphosphonate zoledronic acid decreases tumor growth in bone in mice with defective osteoclasts.Lowering bone mineral affinity of bisphosphonates as a therapeutic strategy to optimize skeletal tumor growth inhibition in vivo.Activation of γδ T cells by bisphosphonates.Visualizing mineral binding and uptake of bisphosphonate by osteoclasts and non-resorbing cells.CMT3 alters mitochondrial function in murine osteoclast lineage cells.Inhibition of protein prenylation by bisphosphonates causes sustained activation of Rac, Cdc42, and Rho GTPases.Mevalonate kinase deficiency leads to decreased prenylation of Rab GTPases.Effects of tiludronate and ibandronate on the secretion of proinflammatory cytokines and nitric oxide from macrophages in vitro.Antagonistic effects of different classes of bisphosphonates in osteoclasts and macrophages in vitro.Identification of a novel phosphonocarboxylate inhibitor of Rab geranylgeranyl transferase that specifically prevents Rab prenylation in osteoclasts and macrophages.A class III semaphorin (Sema3e) inhibits mouse osteoblast migration and decreases osteoclast formation in vitro.
P50
Q24310432-CF7B808E-B871-4FE9-945F-8FDEF885AB14Q24322122-215DA357-84BC-449C-B32C-61BB8D038F02Q24673342-9C475513-4D49-498F-B984-091ED400A575Q27316833-71D337F1-E41B-4DA2-BDE6-9229399BCB5AQ28661603-009C9D9A-1838-4AC0-AB89-B18968731703Q33632255-9BEC9A50-B540-47EA-8AF7-9C86D69F12BDQ33913012-EF1EF607-254B-4759-B7DF-8D80D9802054Q34009569-27629BED-316A-473C-81FF-F7EC024B7EE1Q34098297-932AD1D6-DF05-4842-901F-0AB4CA5ACCECQ34403310-045050E7-CDB8-4D84-B0A6-4DA8FBFC88FAQ34438194-4958858B-D234-4DB4-8D33-83DB636C7EBFQ34523564-C50809D0-A4AD-41FA-9CA2-3BD15B314CC2Q34682137-4EDF62B5-9C3B-4611-8D3C-54D2D4B8139DQ34945422-F00C5789-8F9F-41FB-B83F-FC25EA0F0E39Q35107102-6878B965-1653-4621-A2DB-E482554F7CAAQ35156294-AB56EA29-B872-4CE2-B0F0-2FC15E85DCB0Q35194022-68ED20B4-9E4E-4119-9CB7-8BD3A0845150Q35688200-B3D9E990-C1EC-4AAD-8CFE-A7280BE923B2Q35872753-9B8EA3A9-12E4-4810-BFB9-43F90E53026EQ36043987-BC0C1E0F-F642-4E54-B4C6-5D43E4566832Q36290218-E4CDE40C-FD62-4D4B-918B-F0F0483C0E07Q36633778-BA7C6B6C-2641-45ED-94FF-294FC5EF5FCDQ36997869-35AD5B02-3EEF-42CD-8CC0-41B725CBB8E4Q37119792-D0B54632-D5BE-4FBC-B69A-4660D2F4CAADQ37781070-D66C1BD6-0C0F-4E37-8E5D-B8058ED7322AQ37812800-89818CF0-FC1A-4028-84B0-C643F82E16D1Q39640689-24A7A53B-050E-46BA-B19C-3530CB425ADCQ39714489-41EF5721-0292-4F8A-BF6E-D2B52C5B157FQ39822639-C01BD49A-CC82-4A41-913C-3D19BC4E7FD0Q39851518-44B1CF8E-6258-42A1-AA7D-E355DBF853C2Q39923098-10485555-A0AA-4BDD-BBF4-7A317F9637DDQ39924204-18AB02D3-1BAE-4092-930C-2E1CBE8AEADFQ40004851-08515F57-9FC3-408A-ACA1-C1F0D306F186Q40045365-5BBED30C-C0A6-4C9B-87ED-36D936881162Q40273935-BC652784-4370-419E-BCCC-961381A4D057Q40625676-5BCBD41E-94D8-41C2-811A-48F6BBB87DC9Q40641568-10B23770-107F-47F3-8E76-F6B3D323A484Q40672811-AB9379EE-0EA8-4636-ACE5-2410407716FFQ40777493-BC336040-08C3-4735-A2FA-EB302253E592Q40817034-E82DFD85-340C-4DCF-B2E8-FC4B7F3A3A86
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Michael J Rogers
@es
Michael J Rogers
@nl
Michael J Rogers
@sl
Michael J. Rogers
@en
type
label
Michael J Rogers
@es
Michael J Rogers
@nl
Michael J Rogers
@sl
Michael J. Rogers
@en
prefLabel
Michael J Rogers
@es
Michael J Rogers
@nl
Michael J Rogers
@sl
Michael J. Rogers
@en
P106
P1153
55481881300
P21
P31
P496
0000-0002-1818-9249